FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172071444> ?p ?o ?g. }

• W3172071444 endingPage "2662" @default.
• W3172071444 startingPage "2662" @default.
• W3172071444 abstract "Introduction: Several immune checkpoint inhibitors (CPIs) are under clinical development in hepatocellular carcinoma (HCC) and the field is advancing rapidly. In this comprehensive review, we discuss published results and report on ongoing clinical trials. Methods: A literature search was carried out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were included as well. The search was updated 5 March 2021. We evaluated studies with monotherapy CPI's, combinations of CPI's and combinations of CPI's with other treatment modalities separately. Only studies with at least 10 included patients were considered. Results: We identified 2649 records published in the English language literature. After review, 29 studies remained, including 12 studies with preliminary data only. The obtained overall response rate of PD-1/PDL-1 monotherapy in phase II studies in the second-line setting was 15-20% with disease control in approximately 60% of patients. The responses were of long duration in a subset of patients. Furthermore, the safety profiles were manageable. However, a phase III study comparing nivolumab with sorafenib in the first-line setting and a phase III study evaluating pembrolizumab versus best supportive care in the second-line setting did not meet their prespecified endpoints. More recently, a phase I/II study of nivolumab and ipilimumab has resulted in a response rate of approximately 30% with a median OS of 22 months in the second-line setting. Multiple trials have been initiated to evaluate CPIs in combination with molecularly targeted drugs, especially anti-angiogenic drugs or local therapy. A phase III study investigating atezolizumab plus bevacizumab versus sorafenib in the first-line setting showed significantly increased survival in the combination arm. Conclusions: The combination of atezolizumab and bevacizumab represents a new standard of care in the first-line setting for fit patients with preserved liver function. CPIs can produce durable tumor remission and induce long-standing anti-tumor immunity in a subgroup of patients with advanced HCC. Although phase III trials of CPI monotherapy have been negative, the combination of PD-1/PD-L1 inhibitors with other anti-angiogenic drugs, CTLA-4 inhibitors or other modalities may result in new treatment options for patients with HCC. Research on predictive biomarkers is crucial for further development of CPIs in HCC." @default.
• W3172071444 created "2021-06-22" @default.
• W3172071444 creator A5021332348 @default.
• W3172071444 creator A5041226551 @default.
• W3172071444 creator A5051309443 @default.
• W3172071444 creator A5090876784 @default.
• W3172071444 date "2021-06-16" @default.
• W3172071444 modified "2023-09-27" @default.
• W3172071444 title "Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma" @default.
• W3172071444 cites W1876374370 @default.
• W3172071444 cites W1910012553 @default.
• W3172071444 cites W1963920328 @default.
• W3172071444 cites W1971837077 @default.
• W3172071444 cites W1985398175 @default.
• W3172071444 cites W1986128216 @default.
• W3172071444 cites W1994193851 @default.
• W3172071444 cites W2000307707 @default.
• W3172071444 cites W2030612376 @default.
• W3172071444 cites W2039123767 @default.
• W3172071444 cites W2049553585 @default.
• W3172071444 cites W2052730188 @default.
• W3172071444 cites W2060123467 @default.
• W3172071444 cites W2073830661 @default.
• W3172071444 cites W2080202443 @default.
• W3172071444 cites W2108018825 @default.
• W3172071444 cites W2132561915 @default.
• W3172071444 cites W2136977965 @default.
• W3172071444 cites W2143163879 @default.
• W3172071444 cites W2147172608 @default.
• W3172071444 cites W2162667703 @default.
• W3172071444 cites W2268557403 @default.
• W3172071444 cites W2275872217 @default.
• W3172071444 cites W2340636398 @default.
• W3172071444 cites W2499029168 @default.
• W3172071444 cites W2519279652 @default.
• W3172071444 cites W2530004119 @default.
• W3172071444 cites W2546700240 @default.
• W3172071444 cites W2560367415 @default.
• W3172071444 cites W2560499218 @default.
• W3172071444 cites W2572174216 @default.
• W3172071444 cites W2589962984 @default.
• W3172071444 cites W2591717879 @default.
• W3172071444 cites W2606367731 @default.
• W3172071444 cites W2607253489 @default.
• W3172071444 cites W2618584271 @default.
• W3172071444 cites W2630573111 @default.
• W3172071444 cites W2724506765 @default.
• W3172071444 cites W2752695375 @default.
• W3172071444 cites W2754580992 @default.
• W3172071444 cites W2755693293 @default.
• W3172071444 cites W2759382352 @default.
• W3172071444 cites W2766379919 @default.
• W3172071444 cites W2767219591 @default.
• W3172071444 cites W2767241904 @default.
• W3172071444 cites W2775356055 @default.
• W3172071444 cites W2787358630 @default.
• W3172071444 cites W2790370205 @default.
• W3172071444 cites W2791328450 @default.
• W3172071444 cites W2792376809 @default.
• W3172071444 cites W2792937256 @default.
• W3172071444 cites W2795334950 @default.
• W3172071444 cites W2797744035 @default.
• W3172071444 cites W2800160190 @default.
• W3172071444 cites W2803637437 @default.
• W3172071444 cites W2805592007 @default.
• W3172071444 cites W2809889937 @default.
• W3172071444 cites W2886119834 @default.
• W3172071444 cites W2887004395 @default.
• W3172071444 cites W2888270102 @default.
• W3172071444 cites W2889835879 @default.
• W3172071444 cites W2890487472 @default.
• W3172071444 cites W2891760302 @default.
• W3172071444 cites W2892757136 @default.
• W3172071444 cites W2897612290 @default.
• W3172071444 cites W2898561188 @default.
• W3172071444 cites W2908573150 @default.
• W3172071444 cites W2911028788 @default.
• W3172071444 cites W2912094423 @default.
• W3172071444 cites W2913248633 @default.
• W3172071444 cites W2917766341 @default.
• W3172071444 cites W2920764569 @default.
• W3172071444 cites W2921608255 @default.
• W3172071444 cites W2943025075 @default.
• W3172071444 cites W2947077957 @default.
• W3172071444 cites W2947105080 @default.
• W3172071444 cites W2947312239 @default.
• W3172071444 cites W2952311394 @default.
• W3172071444 cites W2955008365 @default.
• W3172071444 cites W2957852424 @default.
• W3172071444 cites W2965242861 @default.
• W3172071444 cites W2977722669 @default.
• W3172071444 cites W2981627164 @default.
• W3172071444 cites W2990323558 @default.
• W3172071444 cites W2990602950 @default.
• W3172071444 cites W2994632555 @default.
• W3172071444 cites W3004098263 @default.
• W3172071444 cites W3008514541 @default.
• W3172071444 cites W3008735258 @default.

• next